Canterbury DHB


Diagnostic Criteria

Due to increasing evidence about the differences in outcome based on timing of diagnosis, the 2016 WHO classification of haematopietic malignancies emphasizes the differences between pre-fibrotic/early phase PMF (median survival >15 years) and overt phase PMF (median survival 3–7 years), see Rumi E, et al. (2017),1 table 2, page 3.

A bone marrow biopsy is important in this classification, especially in distinguishing between PMF and ET. A condition similar to PMF can develop in patients with pre-existing PV or ET (see Polycythaemia Vera and Essential Thrombocythaemia). Exclude secondary causes before diagnosing primary myelofibrosis.

About this Canterbury DHB document (6242):

Document Owner:

Bridgett McDiarmid (see Who's Who)

Last Reviewed:

August 2018

Next Review:

April 2021


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 6242